QNCX NASDAQ
Quince Therapeutics, Inc.
1W: -5.8%
1M: -9.2%
3M: +72.0%
YTD: +873.3%
1Y: +1702.5%
3Y: +2395.7%
5Y: -68.8%
$29.20
-1.48 (-4.82%)
Weekly Expected Move ±10.0%
$23
$26
$29
$32
$35
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
17 relationships17
As Filer
counterparties named
0
As Counterparty
mentioned by others
6
Rel. Types
2021-05-18
Earliest Filing
2023-10-23
Latest Filing
partner: 8
target: 5
customer: 1
investor: 1
acquirer: 1
supplier: 1
Counterparties (Filed by QNCX)
17 relationshipsCompanies named in QNCX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| EryDel S.p.A | — | target | Target company acquired by Quince Therapeutics, Inc. | 2023-10-23 | View |
| Shareholder Representative Services LLC | — | partner | Representative, agent, and attorney-in-fact for the EryDel Shareholders in the Stock Purchase Agreement. | 2023-10-23 | View |
| Erydel S.p.A. | — | customer | Italian company that received advances under a promissory note from Erydel Italy, Inc. | 2023-09-06 | View |
| EryDel Italy, Inc. | — | target | Target company in the acquisition of all outstanding equity interests. | 2023-07-24 | View |
| EryDel S.p.A | — | target | Target company in the acquisition of all outstanding equity interests. | 2023-07-24 | View |
| Shareholder Representative Services LLC | — | investor | Representative, agent, and attorney-in-fact for the EryDel Shareholders. | 2023-07-24 | View |
| American Stock Transfer & Trust Company, LLC | AIG | partner | Serves as Rights Agent and transfer agent for the Rights Agreement. | 2023-04-05 | View |
| Lighthouse Pharmaceuticals, Inc. | — | acquirer | Acquired Quince Therapeutics' legacy small molecule protease inhibitor portfolio including COR388, COR588, COR803, and C | 2023-01-27 | View |
| ICON Clinical Research, LLC | — | supplier | Entered into a Sublease Agreement for office premises. | 2022-06-10 | View |
| Novosteo Inc. | — | target | Target company acquired by Cortexyme, Inc. in a merger completed on May 19, 2022. | 2022-05-20 | View |
| Fortis Advisors LLC | — | partner | Securityholders' representative in the Merger Agreement between Cortexyme, Inc. and Novosteo Inc. | 2022-05-20 | View |
| Novosteo Inc. | — | target | Target company in the merger agreement with Cortexyme, Inc. | 2022-05-12 | View |
| Quince Merger Sub I, Inc. | — | partner | Wholly owned subsidiary of Cortexyme, Inc. used as a party in the merger agreement. | 2022-05-12 | View |
| Quince Merger Sub II, LLC | — | partner | Wholly owned subsidiary of Cortexyme, Inc. used as a party in the merger agreement. | 2022-05-12 | View |
| Fortis Advisors LLC | — | partner | Representative of the Participating Securityholders in the merger agreement. | 2022-05-12 | View |
| Jefferies LLC | JEF | partner | Sales agent for the Open Market Sale Agreement | 2021-12-23 | View |
| Verily Life Sciences LLC | — | partner | Third Amendment to Sub-Sublease for office premises | 2021-05-18 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-02 | Officer/Director Change | View | |
| 2026-09-14 | Acquisition/Disposition; Officer/Director Change; Exhibits | Acquisition | View |
| 2026-09-04 | Delisting Notice | View | |
| 2026-08-27 | Officer/Director Change | View | |
| 2026-08-17 | Other Events; Exhibits | View | |
| 2026-08-14 | Earnings Release; Exhibits | View | |
| 2026-07-31 | Officer/Director Change | View | |
| 2026-07-30 | Other Events; Exhibits | View | |
| 2026-06-26 | Bylaws Amendment; Exhibits | View | |
| 2026-06-26 | Other Events | View | |
| 2026-06-11 | Shareholder Vote | View | |
| 2026-05-21 | Other Events | View | |
| 2026-05-18 | Material Agreement; Acquisition/Disposition; Unregistered Equity Sales; Officer/Director Change; Byl | Agreement Acquisition | View |
| 2026-05-18 | Regulation FD; Exhibits | View | |
| 2026-04-28 | Other Events | View | |
| 2026-04-22 | Officer/Director Change | View | |
| 2026-04-09 | Bylaws Amendment; Exhibits | View | |
| 2026-03-30 | Termination of Agreement; Regulation FD; Exhibits | View | |
| 2026-02-12 | Results of Operations and Financial Condition; Other Events | View | |
| 2026-02-02 | Departure/Election of Directors; Appointment of Officers | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR